Immunoproliferative disorder
MONDO:0021334Disorders characterized by abnormal proliferation of primary cells of the immune system or by excessive production of immunoglobulins.
Also known as: immunoproliferative disorder, Disorder, Immunoproliferative, Disorders, Immunoproliferative, Immunoproliferative Disorder, Immunoproliferative Disorders, Immunoproliferative disease, Immunoproliferative disorder
19 clinical trials for this condition and its sub-types, 19 tagged with Immunoproliferative disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Gene therapy builds Cancer-Killing cells inside you – no lab needed
Disease control Recruiting nowThis early-stage trial tests a new gene therapy called KLN-1010 for people with multiple myeloma that has come back or stopped responding to treatment. Instead of removing cells and engineering them in a lab, this therapy works inside the body to create special immune cells that …
Phase 1 • Sponsor: Kelonia Therapeutics, Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New cell therapy aims to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis phase 2 trial is testing a new treatment called Orca-T for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Orca-T is a personalized cell therapy made from a donor's blood that includes stem cells and immune cells. The goal is to see if it can impr…
Phase 2 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New pill combo shows promise for tough brain cancer
Disease control Recruiting nowThis study tests an experimental oral drug called emavusertib (CA-4948), taken alone or with ibrutinib, in adults with relapsed or refractory primary central nervous system lymphoma (PCNSL). The trial has multiple parts to find the safest dose and see if the drug shrinks tumors. …
Phase 1/2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC